On May 21, 2026 Servier reported that it will present new and updated data at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting May 29 – June 2 in Chicago. Presentations will span across a range of rare cancers, including IDH-mutated glioma and adenoid cystic carcinoma (ACC).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Servier’s upcoming presentations at ASCO (Free ASCO Whitepaper)—which include updated long-term data in IDH-mutant glioma as well as emerging data from our newer oncology programs—underscore our dedication to delivering transformative medicines to patients with high unmet needs," said Becky Martin, PhD, Chief of Medical, Servier Pharmaceuticals. "Together, these programs demonstrate the continued evolution of Servier’s oncology portfolio and our growing presence in rare oncology."
Notably, Servier will present updated efficacy and safety data from a long-term analysis of the Phase 3 INDIGO trial of VORANIGO (vorasidenib) in a rapid oral presentation on May 31 at 4:36 p.m. CDT. Key findings from more than three years of follow-up data further support the robust progression-free survival (PFS) and time to next treatment intervention (TTNI) results observed with VORANIGO in previous analyses and confirm the durable and sustained treatment benefit of VORANIGO in Grade 2 IDH-mutant glioma.
Additional data from an exploratory analysis of the INDIGO trial demonstrating long-term treatment with VORANIGO generally led to a sustained decrease in seizure frequency and severity and preservation of quality of life will be presented as well.
Day One Biopharmaceuticals, now part of Servier Group, will also share results from an ongoing Phase 1 trial evaluating investigational compound Emi-Le (emiltatug ledadotin) in an oral presentation on June 1 at 8:24 a.m. CDT. The data reveal that Emi-Le demonstrates favorable tolerability and promising antitumor activity in patients with aggressive ACC who have no available treatment options and a poor prognosis. Further clinical development is ongoing.
In addition, a placebo-controlled trial of vorasidenib in IDH-mutated newly diagnosed Grade 3 astrocytoma led by the Alliance for Clinical Trials in Oncology will be featured in a trial in progress presentation.
A full list of ASCO (Free ASCO Whitepaper) abstracts can be found here. Please visit the Servier booth (#12079) and the Day One booth (#36155) onsite to learn more.
Servier will also present research updates at the European Hematology Association (EHA) (Free EHA Whitepaper) 2026 Congress June 11-14 in Stockholm.
(Press release, Servier, MAY 21, 2026, View Source [SID1234665960])